Exagen reports Q3 EPS (31c), consensus (47c)

Reports Q3 revenue $13.42M, consensus $10.33M. “We believe we are well on pace to deliver record revenue, marked improvement in adjusted EBITDA and growth in AVISE CTD trailing twelve-month ASP for the full-year 2023. I am extremely proud of the team for their efforts this past quarter and we continue to see improvement in key performance metrics which we telegraphed at the start of the year,” said John Aballi, president and CEO of Exagen.